Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Maternal diets high in UPFs may influence children’s health years later

17

Jul 2026

Maternal diets high in UPFs may influence children’s health years later

A narrative review of 84 publications links higher ultra-processed food intake during pregnancy and early childhood with poorer diet quality, maternal complications, childhood obesity, and potential immune, metabolic, and neurodevelopmental effects. The authors identify possible microbiome and biopsychosocial pathways but emphasize that the predominantly observational evidence cannot establish causality.

Blood p-tau217 levels signal cognitive impairment risk years before symptoms emerge

16

Jul 2026

Blood p-tau217 levels signal cognitive impairment risk years before symptoms emerge

Higher baseline plasma p-tau217 was associated with greater 5- and 10-year risks of cognitive impairment and faster cognitive decline among 2,684 cognitively unimpaired adults. Very high levels corresponded to an estimated 38% risk at five years, but selected cohorts and limited long-term data mean routine screening and individualized prediction remain premature.

Experimental drug shows promise against NRAS-driven melanoma

16

Jul 2026

Experimental drug shows promise against NRAS-driven melanoma

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

LIG1 loss reveals new treatment strategy for aggressive breast cancer

16

Jul 2026

LIG1 loss reveals new treatment strategy for aggressive breast cancer

Loss of one copy of the DNA Ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.